APP and early-onset autosomal dominant Alzheimer disease: For this reason developers of pharmaceuticals for Alzheimer’s disease have expended enormous efforts to identify compounds that modify γ-secretase-mediated processing of APP without affecting the enzyme’s processing of Notch [68].